Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis.
Buparvaquone (Butalex), a therapeutic for theileriosis, has been shown to have anti-leishmanial activity in vitro. Seven dogs with symptomatic, parasitologically positive, canine visceral leishmaniosis were treated with Butalex at 5 mg kg(-1) body weight using four doses over 12 days. Two animals showed minor clinical improvement (growth of healthy hair) but all remained parasitologically positive and disease progression was not halted.
Vexenat
J A
JA
Medical Parasitology Laboratory, University of Brasilia, Brasilia DF, Brazil.
Croft
S L
SL
Furtado Campos
J H
JH
Miles
M A
MA
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D007273:Injections, Intramuscular / Q000662:veterinary; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*
D000981:Antiprotozoal Agents; D009285:Naphthoquinones; C046326:buparvaquone